Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 631,300 shares, an increase of 437.3% from the January 15th total of 117,500 shares. Based on an average daily volume of 3,650,000 shares, the short-interest ratio is presently 0.2 days. Approximately 3.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Stock Performance

Shares of Virpax Pharmaceuticals stock traded down $0.01 during midday trading on Wednesday, reaching $0.26. The company had a trading volume of 125,537 shares, compared to its average volume of 436,467. The stock has a fifty day simple moving average of $0.33 and a 200 day simple moving average of $0.60. Virpax Pharmaceuticals has a 1-year low of $0.23 and a 1-year high of $5.48.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.